Search

Displaying results 4281 - 4290 of 7452 in total
  1. Drug

    Tanezumab

    go.drugbank.com/drugs/DB12335
    Investigational

    Tanezumab has been investigated for the treatment of Osteoarthritis, Knee and Neuralgia, Postherpetic.

  2. Drug

    E-7820

    go.drugbank.com/drugs/DB12505
    Investigational

    E7820 has been investigated for the treatment of Colon Cancer and Rectal Cancer.

  3. Drug

    Apaziquone

    go.drugbank.com/drugs/DB12593
    Investigational

    Apaziquone has been investigated for the treatment of Bladder Cancer and Bladder Neoplasms.

  4. Drug

    Vixotrigine

    go.drugbank.com/drugs/DB11706
    Investigational

    Vixotrigine has been investigated for the treatment of Bipolar Disorder and Bipolar Depression.

  5. Drug

    GPI-1485

    go.drugbank.com/drugs/DB05814
    Investigational

    GPI 1485 is being studied in phase 2 clinical trials for the treatment of Parkinson's disease and post-prostatectomy erectile dysfunction and in pre-clinical development for HIV related dementia and neuropathy

  6. Drug

    Strontium malonate

    go.drugbank.com/drugs/DB05732
    Investigational

    Strontium malonate is being developed as a novel orally available pharmaceutical for the treatment and prevention of osteoporosis. It is being developed by Osteologix Inc.

  7. Drug

    Cannabinor

    go.drugbank.com/drugs/DB05048
    Experimental

    Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.

  8. Drug

    Cefovecin

    go.drugbank.com/drugs/DB11505
    ExperimentalVet approved

    It is the first single-dose injectable antibiotic for dogs and cats that assures owner compliance with dosing for the animal. … Cefovecin is a cephalosporin antibiotic used for the treatment of skin infections in cats and dogs.

  9. Drug

    Arbaclofen Placarbil

    go.drugbank.com/drugs/DB08892
    Investigational

    On May 20th, 2013, XenoPort announced plans to terminate the development of Arbaclofen Placerbil for the treatment of multiple sclerosis. … It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties.

  10. Drug

    Troxacitabine

    go.drugbank.com/drugs/DB04961
    Investigational

    There has been growing interest in its development for the treatment of patients with refractory lymphoproliferative conditions.